The impact of next generation sequencing on the analysis of breast cancer susceptibility: A role for extremely rare genetic variation?

Clinical Genetics

Volumn 84, Issue 5, 2013, Pages 407-414

  Hilbers, Fsm ^a   Vreeswijk, Mpg ^a   van Asperen, Cj ^a   Devilee, P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Familial risk; Genetics; Sequencing technology

Indexed keywords

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COPY NUMBER VARIATION; GENE FREQUENCY; GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC DRIFT; GENETIC VARIABILITY; HERITABILITY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BREAST CANCER; FAMILIAL RISK; GENETICS; SEQUENCING TECHNOLOGY;

ALLELES; BREAST NEOPLASMS; FEMALE; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASM PROTEINS; RISK FACTORS;

EID: 84885864788     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12256     Document Type: Review

References (90)

1. Lalloo F, Evans DG. Familial breast cancer. Clin Genet 2012: 82: 105-114.
2. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000: 83: 1301-1308.
3. Easton DF. How many more breast cancer predisposition genes are there? Breast Cancer Res 1999: 1: 14-17.
4. Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999: 91: 943-949.
5. Breast Cancer infromation Core. Retrieved July 12, 2013 http://research.nhgri.nih.gov/projects/bic/index.shtml.
6. Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002: 11: 329-336.
7. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001: 68: 410-419.
8. Michailidou K, Hall P, Gonzalez-Neira A et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013: 45: 353-2.
9. Spurdle AB, Whiley PJ, Thompson B et al. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet 2012: 49: 525-532.
10. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990: 250: 1233-1238.
11. Nelen MR, van Staveren WC, Peeters EA et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997: 6: 1383-1387.
12. Hemminki A, Markie D, Tomlinson I et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998: 391: 184-187.
13. Jenne DE, Reimann H, Nezu J et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998: 18: 38-43.
14. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998: 392: 402-405.
15. Keller G, Vogelsang H, Becker I et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999: 155: 337-342.
16. Pharoah PD, Guilford P, Caldas C; International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001: 121: 1348-1353.
17. Ginsburg OM, Akbari MR, Aziz Z et al. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 2009: 8: 563-567.
18. Rapakko K, Allinen M, Syrjakoski K et al. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 2001: 84: 116-119.
19. FitzGerald MG, Marsh DJ, Wahrer D et al. Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene 1998: 17: 727-731.
20. Guenard F, Pedneault CS, Ouellette G et al. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genet Test Mol Biomarkers 2010: 14: 515-526.
21. Schrader KA, Masciari S, Boyd N et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet 2011: 48: 64-68.
22. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991: 325: 1831-1836.
23. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010: 362: 1909-1919.
24. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006: 38: 873-875.
25. Meijers-Heijboer H, van den Ouweland A, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002: 31: 55-59.
26. Seal S, Thompson D, Renwick A et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006: 38: 1239-1241.
27. Rahman N, Seal S, Thompson D et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007: 39: 165-167.
28. Steffen J, Nowakowska D, Niwinska A et al. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 2006: 119: 472-475.
29. Solyom S, Aressy B, Pylkas K et al. Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med 2012: 4: 122-123.
30. De Brakeleer S, De Grève J, Loris R et al. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum Mutat 2010: 31: E1175-E1185.
31. Ratajska M, Antoszewska E, Piskorz A et al. Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat 2012: 131: 89-97.
32. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010: 42: 410-414.
33. Bartkova J, Tommiska J, Oplustilova L et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008: 2: 296-316.
34. Heikkinen K, Rapakko K, Karppinen SM et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006: 27: 1593-1599.
35. Clague J, Wilhoite G, Adamson A, Bailis A, Weitzel JN, Neuhausen SL. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS One 2011: 6: e25632.
36. De Leeneer K, Van Bockstal M, De Brouwer S et al. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing. Breast Cancer Res Treat 2012: 133: 393-398.
37. Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG. BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer. Breast Cancer Res Treat 2008: 111: 505-509.
38. Thompson ER, Boyle SE, Johnson J et al. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat 2012: 33: 95-99.
39. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 2010: 124: 857-861.
40. Uhrhammer N, Delort L, Bignon YJ. Rad50 c.687delT does not contribute significantly to familial breast cancer in a French population. Cancer Epidemiol Biomarkers Prev 2009: 18: 684-685.
41. Tommiska J, Seal S, Renwick A et al. Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer 2006: 118: 2911-2916.
42. Loveday C, Turnbull C, Ruark E et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012: 44: 475-476.
43. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001: 21: 1-18.
44. Antoniou AC, Pharoah PD, McMullan G et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002: 86: 76-83.
45. Cui J, Antoniou AC, Dite GS et al. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer. Am J Hum Genet 2001: 68: 420-431.
46. Keinan A, Clark AG. Recent explosive human population growth has resulted in an excess of rare genetic variants. Science 2012: 336: 740-743.
47. Nickels S, Truong T, Hein R et al. Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 2013: 9: e1003284.
48. Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011: 22 (Suppl. 1): i11-i17.
49. Gracia-Aznarez FJ, Fernandez V, Pita G et al. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One 2013: 8: e55681.
50. Hilbers FS, Meijers CM, Laros JF et al. Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling. PLoS One 2013: 8: e55734.
51. Park DJ, Odefrey FA, Hammet F et al. FAN1 variants identified in multiple-case early-onset breast cancer families via exome sequencing: no evidence for association with risk for breast cancer. Breast Cancer Res Treat 2011: 130: 1043-1049.
52. Park DJ, Lesueur F, Nguyen-Dumont T et al. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012: 90: 734-739.
53. Thompson ER, Doyle MA, Ryland GL et al. Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet 2012: 8: e1002894.
54. Howlett NG, Taniguchi T, Olson S et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002: 297: 606-609.
55. Berwick M, Satagopan JM, Ben-Porat L et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 2007: 67: 9591-9596.
56. Garcia MJ, Fernandez V, Osorio A et al. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis 2009: 30: 1898-1902.
57. Shamseldin HE, Elfaki M, Alkuraya FS. Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet 2012: 49: 184-186.
58. Hilbers FS, Wijnen JT, Hoogerbrugge N et al. Rare variants in XRCC2 as breast cancer susceptibility alleles. J Med Genet 2012: 49: 618-620.
59. Rodriguez-Lopez R, Osorio A, Sanchez-Pulido L et al. No mutations in the XRCC2 gene in BRCA1/2-negative high-risk breast cancer families. Int J Cancer 2003: 103: 136-137.
60. Ellis NA, Groden J, Ye TZ et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 1995: 83: 655-666.
61. Prokofyeva D, Bogdanova N, Dubrowinskaja N et al. Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat 2013: 137: 533-539.
62. Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV et al. High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int J Cancer 2012: 130: 2867-2873.
63. Cleary SP, Zhang W, Di NN et al. Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 2003: 63: 1769-1771.
64. Baris HN, Kedar I, Halpern GJ et al. Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome. Isr Med Assoc J 2007: 9: 847-850.
65. Ruark E, Snape K, Humburg P et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 2013: 493: 406-410.
66. Southey MC, Park DJ, Nguyen-Dumont T et al. COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. Breast Cancer Res 2013: 15: 402.
67. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003: 19: 149-150.
68. Zhang S, Royer R, Li S et al. Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011: 121: 353-357.
69. Pal T, Permuth-Wey J, Betts JA et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005: 104: 2807-2816.
70. Rafnar T, Gudbjartsson DF, Sulem P et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011: 43: 1104-1107.
71. Tchernitchko D, Goossens M, Wajcman H. In silico prediction of the deleterious effect of a mutation: proceed with caution in clinical genetics. Clin Chem 2004: 50: 1974-1978.
72. Chenevix-Trench G, Spurdle AB, Gatei M et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002: 94: 205-215.
73. Goldgar DE, Healey S, Dowty JG et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2011: 13: R73.
74. Carvalho MA, Couch FJ, Monteiro AN. Functional assays for BRCA1 and BRCA2. Int J Biochem Cell Biol 2007: 39: 298-310.
75. Osorio A, Endt D, Fernandez F et al. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet 2012: 21: 2889-2898.
76. Roeb W, Higgins J, King MC. Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum Mol Genet 2012: 21: 2738-2744.
77. Bell DW, Kim SH, Godwin AK et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007: 121: 2661-2667.
78. Shaag A, Walsh T, Renbaum P et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 2005: 14: 555-563.
79. Scott SP, Bendix R, Chen P, Clark R, Dork T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A 2002: 99: 925-930.
80. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971: 68: 820-823.
81. Ponder B. Cancer. Gene losses in human tumours. Nature 1988: 335: 400-402.
82. Collins N, McManus R, Wooster R et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995: 10: 1673-1675.
83. Gudmundsson J, Johannesdottir G, Bergthorsson JT et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995: 55: 4830-4832.
84. Osorio A, de la Hoya M, Rodriguez-Lopez R et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002: 99: 305-309.
85. Tung N, Miron A, Schnitt SJ et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010: 12: R95.
86. Broeks A, Urbanus JH, Floore AN et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet 2000: 66: 494-500.
87. Mohammadi L, Vreeswijk MP, Oldenburg R et al. A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer 2009: 9: 211.
88. Spurdle AB, Healey S, Devereau A et al. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012: 33: 2-7.
89. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 2013: 31: 1267-1270.
90. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 2002: 20: 1480-1490.